Tag: psychiatric
-
Breakthrough Status Given Parkinson’s Psychosis Drug
2 September 2014. Acadia Pharmaceuticals says the U.S. Food and Drug Administration designated its drug candidate pimavanserin as a breakthrough therapy for the treatment of psychosis associated with Parkinson’s disease. Acadia is a biopharmaceutical company in San Diego specializing in neurological and central nervous system disorders. Pimavanserin is Acadia’s lead therapy candidate, to be offered…
-
Medical Centers to Develop Brain Signal Tracking, Therapies
28 May 2014. Massachusetts General Hospital in Boston and University of California in San Francisco are developing technologies to analyze brain activity and deliver near real-time neural stimulation therapies. The five-year project is funded by grants from Defense Advanced Research Projects Agency (DARPA) of $30 million and $26 million respectively to Mass. General and UC-San…
-
Diagnostic Software Developed to Analyze Video for Autism
22 May 2014. Computer scientists and medical researchers at Duke University in North Carolina developed software that uses computer vision to analyze video of an infant’s behavior for signs of autism spectrum disorder. The team from the lab of Duke computer engineering professor Guillermo Sapiro — with colleagues from Duke, University of Minnesota, and University…
-
Shire to End Major Depression Drug Booster Development
7 February 2014. Shire PLC, a pharmaceutical company in the U.K., will end trials of its drug Vyvanse as a supplement to anti-depressants for treating major depressive disorder. The company made the decision following results of two late-stage clinical trials that show the drug failed to meet the studies’ effectiveness objectives. Vyvanse (lisdexamfetamine dimesylate) is…
-
Avanir, Concert in Licensing Deal for Neurological Drugs
The biopharmaceutical company Avanir Pharmaceuticals Inc. in Aliso Viejo, California and the biotechnology firm Concert Pharmaceuticals in Lexington, Massachusetts have agreed on a deal that licenses Concert’s drug-development technology to design treatments for neurological and psychiatric disorders. While the companies did not disclose financial details, the industry Web site Xconomy says the deal can provide…
-
Neural Network Simulates Human Schizophrenia Symptoms
A research team from Yale University in New Haven, Connecticut and University of Texas in Austin developed a simulation of schizophrenia using a computer network model. Their findings appear in the April issue of the journal Biological Psychiatry (paid subscription required). The researchers used a virtual computer model called a neural network to simulate the…
-
Antidepressants Aid in Long-Term Stroke Recovery
A study at University of Iowa in Iowa City finds stroke victims can benefit from a brief treatment of antidepressants, with physical recovery continuing many months after the medication is stopped. The results of the study appeared in a recent issue of the American Journal of Geriatric Psychiatry (paid subscription required). A team led by…
-
Partnership to Develop Psychiatric Treatments
Aestus Therapeutics in North Brunswick, New Jersey) and Eisai Inc. in Woodcliff Lake, New Jersey will collaborate on research and development of novel therapeutics for the treatment of psychiatric disorders. The collaboration will cover pre-clinical validation of potential therapeutics leading to clinical proof-of-concept studies. Aestus says it has previously identified products with the potential to…